ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.41 Million EUR | -19.08% |
| 2022 | -4.1 Million EUR | 30.96% |
| 2021 | -5.95 Million EUR | -100.54% |
| 2020 | -2.96 Million EUR | -232.62% |
| 2019 | 2.23 Million EUR | 131.74% |
| 2018 | -7.05 Million EUR | -6.25% |
| 2017 | -6.63 Million EUR | 72.39% |
| 2016 | -24.03 Million EUR | -55.33% |
| 2015 | -15.47 Million EUR | -154.97% |
| 2014 | -6.06 Million EUR | 38.12% |
| 2013 | -9.8 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.58 Million EUR | 0.0% |
| 2023 Q4 | -592 Thousand EUR | 0.0% |
| 2023 FY | -4.89 Million EUR | -19.08% |
| 2023 Q1 | -1.11 Million EUR | 53.66% |
| 2023 Q2 | -2.92 Million EUR | -162.48% |
| 2023 Q3 | -592 Thousand EUR | 79.75% |
| 2022 Q3 | -827 Thousand EUR | 74.03% |
| 2022 Q2 | -3.18 Million EUR | -159.39% |
| 2022 Q1 | -1.22 Million EUR | 74.21% |
| 2022 Q4 | -2.4 Million EUR | -190.69% |
| 2022 FY | -4.1 Million EUR | 30.96% |
| 2021 Q2 | -2.99 Million EUR | -131.55% |
| 2021 Q3 | -1.68 Million EUR | 43.79% |
| 2021 Q4 | -4.76 Million EUR | -182.83% |
| 2021 FY | -5.95 Million EUR | -100.54% |
| 2021 Q1 | -1.29 Million EUR | 45.9% |
| 2020 FY | -2.96 Million EUR | -232.62% |
| 2020 Q4 | -2.39 Million EUR | -148.05% |
| 2020 Q3 | -963.5 Thousand EUR | 19.37% |
| 2020 Q2 | -1.19 Million EUR | -129.59% |
| 2020 Q1 | -520.49 Thousand EUR | 59.08% |
| 2019 FY | 2.23 Million EUR | 131.74% |
| 2019 Q1 | -723 Thousand EUR | 48.08% |
| 2019 Q4 | -1.27 Million EUR | -135.77% |
| 2019 Q2 | -1.82 Million EUR | -152.56% |
| 2019 Q3 | -539.5 Thousand EUR | 70.45% |
| 2018 Q2 | -1.49 Million EUR | 0.0% |
| 2018 Q1 | -1.49 Million EUR | 20.38% |
| 2018 FY | -7.05 Million EUR | -6.25% |
| 2018 Q4 | -1.39 Million EUR | 0.0% |
| 2018 Q3 | -1.39 Million EUR | 6.67% |
| 2017 FY | -6.63 Million EUR | 72.39% |
| 2017 Q3 | -1.87 Million EUR | -29.73% |
| 2017 Q4 | -1.87 Million EUR | 0.0% |
| 2017 Q1 | -1.44 Million EUR | 71.09% |
| 2017 Q2 | -1.44 Million EUR | 0.0% |
| 2016 Q2 | -7.02 Million EUR | 0.0% |
| 2016 Q4 | -4.99 Million EUR | 0.0% |
| 2016 Q3 | -4.99 Million EUR | 28.82% |
| 2016 Q1 | -7.02 Million EUR | -53.1% |
| 2016 FY | -24.03 Million EUR | -55.33% |
| 2015 FY | -15.47 Million EUR | -154.97% |
| 2015 Q1 | -3.15 Million EUR | -120.08% |
| 2015 Q3 | -4.58 Million EUR | -45.5% |
| 2015 Q2 | -3.15 Million EUR | 0.0% |
| 2015 Q4 | -4.58 Million EUR | 0.0% |
| 2014 Q1 | -1.6 Million EUR | 0.0% |
| 2014 Q3 | -1.43 Million EUR | 10.64% |
| 2014 FY | -6.06 Million EUR | 38.12% |
| 2014 Q4 | -1.43 Million EUR | 0.0% |
| 2014 Q2 | -1.6 Million EUR | 0.0% |
| 2013 FY | -9.8 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIVAX Société Anonyme | -127.37 Million EUR | 97.321% |
| Adocia SA | -17.62 Million EUR | 80.638% |
| Aelis Farma SA | -6.46 Million EUR | 47.191% |
| Biophytis S.A. | -14.33 Million EUR | 76.195% |
| Advicenne S.A. | -6.45 Million EUR | 47.158% |
| genOway Société anonyme | 2.06 Million EUR | 265.206% |
| IntegraGen SA | -183.77 Thousand EUR | -1756.669% |
| Medesis Pharma S.A. | -4.22 Million EUR | 19.325% |
| Neovacs S.A. | -6.9 Million EUR | 50.605% |
| NFL Biosciences SA | -4.43 Million EUR | 22.987% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -338.427% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -8.758% |
| Sensorion SA | -22.31 Million EUR | 84.707% |
| Theranexus Société Anonyme | -7.64 Million EUR | 55.362% |
| TME Pharma N.V. | -5.62 Million EUR | 39.331% |
| Valbiotis SA | -7.16 Million EUR | 52.346% |
| TheraVet SA | -2.17 Million EUR | -56.866% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 83.182% |
| argenx SE | -417.15 Million EUR | 99.182% |
| BioSenic S.A. | -7.04 Million EUR | 51.534% |
| Celyad Oncology SA | -8.45 Million EUR | 59.655% |
| DBV Technologies S.A. | -85.24 Million EUR | 95.997% |
| Galapagos NV | -88.26 Million EUR | 96.134% |
| Genfit S.A. | -26.58 Million EUR | 87.163% |
| GeNeuro SA | -14.35 Million EUR | 76.235% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 78.666% |
| Innate Pharma S.A. | -12.66 Million EUR | 73.068% |
| Inventiva S.A. | -102.7 Million EUR | 96.678% |
| MaaT Pharma SA | -19.94 Million EUR | 82.891% |
| MedinCell S.A. | -20.97 Million EUR | 83.735% |
| Nanobiotix S.A. | -26.77 Million EUR | 87.259% |
| Onward Medical N.V. | -35.46 Million EUR | 90.379% |
| Oryzon Genomics S.A. | -4.54 Million EUR | 24.998% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 85.156% |
| Oxurion NV | -12.11 Million EUR | 71.825% |
| Pharming Group N.V. | -4.87 Million EUR | 30.075% |
| Poxel S.A. | -28.76 Million EUR | 88.138% |
| GenSight Biologics S.A. | -29.69 Million EUR | 88.51% |
| Transgene SA | -30.01 Million EUR | 88.631% |
| Financière de Tubize SA | -2.14 Million EUR | -59.144% |
| UCB SA | 604 Million EUR | 100.565% |
| Valneva SE | -82.08 Million EUR | 95.843% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 88.168% |